Lytic Bacteriophages Against Bacterial Biofilms Formed by Multidrug-Resistant Pseudomonas aeruginosa , Escherichia coli , Klebsiella pneumoniae , and Staphylococcus aureus Isolated from Burn Wounds.

Autor: Pallavali RR; Department of Microbiology, Yogi Vemana University, Kadapa, India., Degati VL; Department of Microbiology, Yogi Vemana University, Kadapa, India., Narala VR; Department of Zoology, Yogi Vemana University, Kadapa, India., Velpula KK; Department of Cancer Biology and Pharmacology (Peoria), University of Illinois, Chicago, Peoria, Illinois, USA., Yenugu S; Department of Animal Biology, University of Hyderabad, Hyderabad, India., Durbaka VRP; Department of Microbiology, Yogi Vemana University, Kadapa, India.
Jazyk: angličtina
Zdroj: PHAGE (New Rochelle, N.Y.) [Phage (New Rochelle)] 2021 Sep 01; Vol. 2 (3), pp. 120-130. Date of Electronic Publication: 2021 Sep 17.
DOI: 10.1089/phage.2021.0004
Abstrakt: Background: Use of bacteriophages as antibiofilm agents to tackle multidrug-resistant bacteria has gained importance in recent years. Materials and Methods: In this study, biofilm formation by Staphylococcus aureus , Pseudomona aeruginosa , Klebsiella pneumoniae , and Escherichia coli under different growth conditions was studied. Furthermore, the ability of bacteriophages to inhibit biofilm formation was analyzed. Results: Under dynamic growth condition, wherein the medium is renewed for every 12 h, the amount of biomass produced and log 10 colony-forming unit counts of all bacterial species studied was highest when compared with other growth conditions tested. Biomass of biofilms produced was drastically reduced when incubated for 2 or 4 h with bacteriophages vB_SAnS_SADP1, vB_PAnP_PADP4, vB_KPnM_KPDP1, and vB_ECnM_ECDP3. Scanning electron microscopy and confocal laser scanning microscopy analyses indicated that the reduction in biomass was due to the lytic action of the bacteriophages. Conclusions: Results of our study reinforce the concept of developing bacteriophages as alternatives to antibiotics to treat bacterial infections.
Competing Interests: No competing financial interests exist.
(Copyright 2021, Mary Ann Liebert, Inc., publishers.)
Databáze: MEDLINE